Relationships among p53 dosage, longevity, cancer, and HSC function
| p53 Genotype . | Median longevity,* wk . | Cancer incidence,† % . | Aged HSC no.,‡ % . | Aged HSC proliferation,§ % . | Aged HSC reconstitution,‖ % . |
|---|---|---|---|---|---|
| p53−/− | 18 | 100 | ND | ND | ND |
| p53+/− | 52 | 90 | 0.22 | 0.070 | 80 |
| p53+/+ | 118 | 45 | 0.15 | 0.029 | 59 |
| p53+/m | 96 | 6 | 0.08 | 0.019 | 31 |
| p53 Genotype . | Median longevity,* wk . | Cancer incidence,† % . | Aged HSC no.,‡ % . | Aged HSC proliferation,§ % . | Aged HSC reconstitution,‖ % . |
|---|---|---|---|---|---|
| p53−/− | 18 | 100 | ND | ND | ND |
| p53+/− | 52 | 90 | 0.22 | 0.070 | 80 |
| p53+/+ | 118 | 45 | 0.15 | 0.029 | 59 |
| p53+/m | 96 | 6 | 0.08 | 0.019 | 31 |
Age in weeks at which 50% of a p53 cohort died.
Percentage of mice in a p53 cohort that develop cancer in a lifespan.
Percentage of HSCs in total marrow cells from aged (18-20-month-old) mice (Figure 1B).
Percentage of proliferating HSCs in total marrow cells (Figure 2B).
Percentage of hematopoietic system reconstituted by 500 aged HSCs from donors of a given p53 genotype 12 weeks after transplantation (Figure 3).